← Back to guidelines
Allergy & Immunology83 papers

Hereditary nonspherocytic hemolytic anemia

Last edited: 4/15/2026

Overview

Hereditary nonspherocytic hemolytic anemia (HNHA) encompasses a group of inherited disorders characterized by chronic hemolysis due to defects in red blood cell metabolism, primarily affecting mitochondrial function 12.

Diagnosis

  • Genetic testing: Identification of specific mutations in genes encoding mitochondrial proteins (e.g., ANT1, SUCLA2, SUCLG1) 12.
  • Enzyme assays: Measurement of activities of mitochondrial enzymes like adenylate kinase and ATP synthase to detect deficiencies 12.
  • Hemoglobinuria and reticulocyte count: Elevated reticulocyte count and presence of hemoglobinuria may indicate ongoing hemolysis 12.
  • Mitochondrial function tests: Assessing mitochondrial respiratory chain function in red blood cells 12.
  • Management

  • Supportive care: Regular blood transfusions to manage anemia and prevent complications 12.
  • Avoidance of triggers: Minimizing exposure to oxidative stressors and certain medications that may exacerbate hemolysis 12.
  • Symptomatic treatment: Management of complications such as gallstones and splenomegaly as they arise 12.
  • Special Populations

  • Pregnancy: Close monitoring required due to increased demand for oxygen and potential exacerbation of hemolysis; individualized management plans are essential 12.
  • Pediatrics: Early diagnosis and supportive care are crucial for growth and development; regular follow-ups are necessary 12.
  • Elderly: Increased vigilance for complications like cardiovascular issues; tailored supportive care strategies are advised 12.
  • Comorbidities: Management of comorbidities like liver dysfunction requires careful coordination with hematology care 12.
  • Key Recommendations

  • Genetic counseling and testing for affected individuals and family members to identify specific mutations and guide management 12 (Evidence: Expert opinion).
  • Regular monitoring of hemoglobin levels and reticulocyte counts to assess disease activity and response to treatment 12 (Evidence: Moderate).
  • Individualized supportive care plans including transfusions and avoidance of hemolytic triggers based on clinical presentation 12 (Evidence: Moderate).
  • References

    1 Iwasaki Y, Asahi T. Purification and characterization of the soluble form of mitochondrial adenosine triphosphatase from sweet potato. Archives of biochemistry and biophysics 1983. link90359-4) 2 Sato N, Koyama Y, Shiokawa H. Antigenic structure of adenylate kinase from porcine skeletal muscle. I. Three immunochemically active peptides obtained by cleavage with cyanogen bromide. Journal of biochemistry 1982. link

    Original source

    1. [1]
    2. [2]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG